Phase II study of safety and efficacy of alternating R-CHOP and R-HDMA therapy in high-risk diffuse large B-cell lymphoma
Phase 2
- Conditions
- diffuse large B-cell lymphoma
- Registration Number
- JPRN-UMIN000031459
- Lead Sponsor
- Division of Hematology, Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
1 Involvement of central nervous system 2 HBs antigen positive 3 HCV antibody positive 4 HIV antibody positive 5 Active synchronous malignancy 6 Patients who are pregnant, lactating, or possibly pregnant 7 Patients who receive steroid therapy for other diseases 8 Patients with uncontrolled infection 9 Severe allergy to drugs used in this study 10Patients who the researcher judged inappropriate as the subject
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method